

**REMARKS**

Applicant has represented a complete listing of claims.


The only change made herein relative to the allowed claims is to insert punctuation at line 5 of claim 1 (i.e., a semicolon), and to insert the structures into claims 8 and 12. The content of these claims remains the same. In claims 8 and 12, reference previously was made generally to 26-hydroxyepothilones. For purposes of clarity, applicant wishes for the claims to identify the compounds by structure. Thus, the amendments simply restate the same subject matter of the claims; they do not require any additional searching, and they are patentable for the same reasons previous claims 8 and 12 were found to be patentable.

**Summary**

The Examiner is invited to contact the undersigned by telephone, at the number listed below, if there are any issues with this amendment, or if it is believed a telephonic communication would facilitate the issuance of the patent.

Respectfully submitted,

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
609-252-6996

  
\_\_\_\_\_  
Anastasia P. Winslow  
Attorney for Applicants  
Reg. No. 40,875

Date: March 29, 2007